Copper Peptides for Hair: Does GHK-Cu for Hair Growth Actually Work?
Start with our pillar guide: Best Peptides for Skin: Peptide Ingredients in Skincare Ranked by Evidence, or browse all Peptide Science articles.
Copper peptides for hair, mainly GHK-Cu (copper tripeptide-1) and AHK-Cu, are not proven to treat hair loss. The support comes from lab and mouse studies, one small eyebrow study reported secondhand in a 2026 review, and scalp studies where copper peptide was one ingredient among several. A copper serum is a low-risk cosmetic add-on, not a treatment. Evidence: Early / preliminary.
Key takeaways
- A 2026 systematic evidence-mapping review found that clinical evidence for GHK-Cu "remains sparse" across all uses, hair included (Mateescu et al., 2026).
- Every human scalp study we found mixed copper peptide with something else: growth-factor injections (Kapoor & Shome, 2018), laser plus finasteride (Bertin et al., 2018), minoxidil plus dutasteride (Kuceki et al., 2025), or a hydroxy-acid scrub (Patel et al., 2024).
- The widely shared "3-fold better delivery" result is a formulation study in mice, not a human trial (Liu et al., 2024).
- GHK-Cu is "fairly hydrophilic," with "limited permeation" through the skin's outer layer (Ogórek et al., 2025).
- A 2014 review found a weighted average of 3.8% positive copper patch tests and called copper "a very weak sensitizer" (Fage et al., 2014).
This page is the hair hub of our Peptide Science section. For how copper peptides behave on facial skin, see what GHK-Cu does for skin, and for the wider peptide family, see our peptide ingredients ranked by evidence. For non-copper hair peptides and how they compare with minoxidil, see our guide to peptides for hair growth.
Do copper peptides for hair actually work?
We don't know yet, because no published trial has tested a copper peptide on its own for scalp hair loss in humans. The evidence ladder below shows where each type of study sits.
A common reader question is whether a copper serum can stand in for an established hair-loss treatment. The honest answer is that the studies people point to either weren't done in humans or tested copper alongside other active treatments. A 2026 systematic review of 64 records called the human GHK-Cu literature "thin and fragmented" and listed androgenetic alopecia (pattern hair loss) among the conditions that still need well-designed trials (Najafi et al., 2026).
Evidence: Early / preliminary.
What is GHK-Cu for hair, and how is AHK-Cu different?
Both are tripeptides (chains of 3 amino acids) bound to copper. GHK-Cu is the studied one; AHK-Cu has only lab hair data. Our AHK-Cu vs GHK-Cu comparison sets the two side by side.
GHK stands for glycyl-L-histidyl-L-lysine. It occurs naturally in human plasma, saliva and urine and declines with age, according to a narrative review by the peptide's original isolator (Pickart et al., 2015). On ingredient labels, GHK-Cu appears as copper tripeptide-1, which the EU CosIng database classes as a skin-conditioning ingredient, not a drug.
AHK-Cu swaps glycine for alanine. It has no confirmed INCI (label) name; vendors call it "copper tripeptide-3," but we could not confirm that name in CosIng. Its only hair-specific data come from one lab study, in which AHK-Cu at 10⁻¹² to 10⁻⁹ M lengthened isolated human hair follicles and increased dermal papilla cell growth (Pyo et al., 2007). We cover that study in full in our AHK-Cu peptide guide.
| Feature | GHK-Cu | AHK-Cu |
|---|---|---|
| Amino acids | Glycine, histidine, lysine + copper | Alanine, histidine, lysine + copper |
| Label name | Copper tripeptide-1 | No confirmed INCI; vendor name "copper tripeptide-3" not found in CosIng |
| Hair evidence | Lab, mouse, multi-ingredient human scalp studies, one eyebrow study | One ex vivo follicle and cell study |
| Human copper-only scalp trial | None found | None found |
Bottom line: Neither has controlled human scalp data on its own. GHK-Cu simply has more research of every other kind.
One more caution: the 2026 Mateescu review keeps canonical GHK-Cu, GHK-derived peptides and non-GHK copper peptides strictly separate (Mateescu et al., 2026). So GHK-Cu findings can't be borrowed to support AHK-Cu, or the reverse. Evidence: Lab / animal only (AHK-Cu).
What does the human evidence on copper peptides for hair show?
Four small or uncontrolled scalp studies reported benefits, but each combined copper peptide with other treatments, so none shows what copper does alone. One eyebrow study exists only as a mention in a review.
| Patel 2024 | 32 enrolled, 29 completed | 15 days | Hydroxy-acid scrub + serum (copper tripeptide-1, witch hazel, hesperidin, hyaluronic acid, pea protein) + rosemary shampoo; topical | Density +12.48%, thickness +25.36%, flaking −61.24% (all p<0.0001) |
| Kapoor 2018 | 1000 | 8 sessions, every 3 weeks; follow-up to 1 year | Injected: VEGF, bFGF, IGF, KGF (growth factors), thymosin β4, copper tripeptide-1 | Hair fall reduced in 83% (pull test); total hair count up at 1 year (P = 0.002) |
| Bertin 2018 | 4 | Not reported in abstract | Non-ablative fractional laser, then topical finasteride 0.05% + growth factors + copper peptide 1% | Improvement in all 4; photos 2 weeks after last session |
| Kuceki 2025 | 7 men | 5 monthly sessions | Tattoo-machine delivery of 0.5% minoxidil sulfate + 0.1% dutasteride + 1.2% copper peptides (type not specified); topical minoxidil continued | Median top-quadrant hair-loss score 40.0% → 7.5% (P<.001); 5 of 7 reached the regrowth endpoint |
Patel 2024
Result: Density +12.48%, thickness +25.36%, flaking −61.24% (all p<0.0001)
Open-label, single-center, no control group, adults 18–50 with mild to moderate dandruff. One author was employed by the product maker; two were employed or paid by the contract research firm.
Kapoor 2018
Result: Hair fall reduced in 83% (pull test); total hair count up at 1 year (P = 0.002)
Open-label, prospective, single-arm pilot. Funding not stated in the abstract.
Bertin 2018
Result: Improvement in all 4; photos 2 weeks after last session
Case series of androgenetic alopecia. No significant side effects. Funding not stated in the abstract.
Kuceki 2025
Result: Median top-quadrant hair-loss score 40.0% → 7.5% (P<.001); 5 of 7 reached the regrowth endpoint
Retrospective, no control group, men with Norwood III–IV pattern loss who had responded poorly to at least 1 year of standard treatment. No funding; one author declares pharma relationships.
Built from PubMed abstracts and, for Patel 2024 and Kuceki 2025, the full texts. No study isolates the copper peptide.
The dandruff kit. In a 15-day open-label study of 32 adults with mild to moderate dandruff (29 completed), a scrub-plus-serum regimen raised measured hair density by 12.48% and thickness by 25.36% (Patel et al., 2024). Participants also used a provided rosemary shampoo, and there was no control group. The product maker's employee was an author, and two authors were employed or paid by the research firm that ran the study.
The injection pilot. In a 1,000-patient open-label study, scalp injections of a growth-factor formulation containing thymosin β4 and copper tripeptide-1, given every 3 weeks for 8 sessions, reduced hair fall in 83% of patients on pull test (Kapoor & Shome, 2018). Total hair count was still significantly higher at 1 year. With 4 growth factors in the mix, the copper's contribution can't be separated.
Laser and tattoo delivery. A 4-case report used laser followed by finasteride 0.05%, growth factors and copper peptide 1% (Bertin et al., 2018). A 7-man retrospective study delivered minoxidil, dutasteride and 1.2% copper peptides by tattoo machine, and blinded dermatologists and AI scored a drop in median top-quadrant hair loss from 40.0% to 7.5% over 5 months (Kuceki et al., 2025). Minoxidil and dutasteride are established hair-loss drugs, so these results say little about copper.
The eyebrow study. The 2026 Mateescu review mentions an 18-participant split-face eyebrow study with "positive cosmetic hair outcomes" that did not define the GHK-Cu form or local exposure (Mateescu et al., 2026). We could not find the primary paper on PubMed, so we can't report anything beyond that.
Evidence: Early / preliminary.
What do lab and animal studies suggest?
Lab and animal studies show copper peptides can stimulate follicles in cells and rodents. That makes a hair effect plausible, but it doesn't show one in people.
- Mice, topical formulation. A Chinese team built an ionic-liquid microemulsion that improved local GHK-Cu delivery about 3-fold, increased Wnt/β-catenin signaling (a pathway involved in hair growth) and affected VEGF, a blood-vessel growth factor, in mice (Liu et al., 2024). The authors declared no conflicts.
- Mice, injections. A 2020 cell and mouse study tested two injectable growth-factor formulations, one containing copper tripeptide-1. Ingredients were non-toxic in human skin-cell assays, and injected mice retained hair within a 0.25-cm radius of injection sites (Kapoor et al., 2020).
- Older rodent work. A 1991 report on C3H mice studied the follicle-stimulating properties of peptide copper complexes; only the title is indexed, and the peptide isn't specified (Trachy et al., 1991). A 1993 review described an unidentified copper-binding peptide, PC1031, that enlarged follicles in fuzzy rats (Uno & Kurata, 1993).
Two narrative reviews by Loren Pickart's group list hair follicles among the tissues GHK helps heal, without study details (Pickart et al., 2015; Pickart et al., 2014). The Najafi review notes that about 35% of the GHK-Cu primary literature it screened includes Pickart or colleague Anna Margolina of Skin Biology, which "limits the independence of the evidence base" (Najafi et al., 2026). Evidence: Lab / animal only.
Are copper peptides as good as minoxidil?
No human study has compared them. The only "similar to minoxidil" finding came from rats treated with an unidentified copper-binding peptide (Uno & Kurata, 1993).
You may also see the claim that GHK-Cu has "minimal side effects when compared with minoxidil and finasteride." That line appears in the opening sentence of the Liu mouse study (Liu et al., 2024) as background. The study itself did not compare GHK-Cu with either drug.
In the Kuceki study, patients kept using topical minoxidil throughout (Kuceki et al., 2025). Copper peptides were tested alongside a drug, never instead of one. If you use a prescribed hair-loss treatment, discuss any additions with your dermatologist or prescriber. Evidence: Lab / animal only.
Can copper peptides for hair even reach the follicle?
Probably not much from a plain serum. GHK-Cu is water-loving, and the skin's outer layer is oily, so delivery is a real barrier.
A 2025 review describes GHK-Cu as "fairly hydrophilic" with "limited permeation through the lipophilic stratum corneum" (the outermost skin layer) (Ogórek et al., 2025). It adds that skin transport of liposome-encapsulated GHK-Cu has "received little attention," so "encapsulated" marketing claims are largely untested.
Delivery tricks do help in the lab. A 2026 systematic review of 20 studies (18 preclinical, 2 RCTs) reported that microneedles and liposomes "markedly improved" GHK-Cu's transdermal bioavailability, though its clinical outcomes were laser-resurfacing satisfaction and wrinkles, not hair (Mokhtar et al., 2026). Microneedle delivery has not yet been tested in an adequately powered human RCT (Najafi et al., 2026). The about 3-fold delivery gain in the Liu study came from a specialized formulation in mice (Liu et al., 2024).
That may explain why every positive human scalp study used injection, laser or tattoo-machine delivery. For the broader picture, see what penetration studies show about peptides. Evidence: Lab / animal only.
Are copper peptides safe on the scalp?
Topical copper peptides appear low-risk, but no study has looked at long-term scalp safety specifically. Copper allergy is uncommon.
In a review of patch-test data, a weighted average of 3.8% of people with suspected copper-related symptoms or exposure tested positive, and the authors concluded copper is "a very weak sensitizer" that can still cause relevant reactions in a few cases (Fage et al., 2014). The 1,000-patient injection study reported treatment was "well tolerated" (Kapoor & Shome, 2018), and the 4-case laser report saw no significant side effects (Bertin et al., 2018). Those findings apply to multi-ingredient protocols, not a single serum.
For irritation, purging-like flares and allergy signs, see copper peptide side effects and what "copper uglies" are. Evidence: Limited.
Should you try injectable or "research-use" GHK-Cu?
We don't recommend it. Injectable GHK-Cu sold online sits in a gray market with little human safety data.
A 2026 narrative review of peptides marketed directly to patients, including GHK-Cu, describes a "gray market" of unapproved compounds "operating largely outside of regulatory oversight." It concludes that "rigorous human safety data are scarce, and there is potential for serious harm to patients" (Mendias & Awan, 2026). The human injection study above used a defined clinical formulation given by clinicians, which is not the same as a vial labeled "for research use." If you are considering procedures, ask a dermatologist about regulated options. Evidence: Limited.
How do you choose and use copper peptides for hair?
Pick a topical cosmetic product that discloses its copper peptide and strength, patch test it, and treat it as an add-on. No study defines the best concentration or schedule for a scalp serum. For one popular multi-peptide example, see our review of The Ordinary's hair density serum.
The only stated strengths in our evidence set were 1% in the laser protocol (Bertin et al., 2018) and 1.2% in the compounded tattoo solution (Kuceki et al., 2025). Neither tells you what a serum alone should contain.
We found no interaction data for copper peptides with minoxidil or retinoids on the scalp. Giving any hair product several months before judging it is clinic convention, since hair cycles are slow, but no copper peptide study supports a specific timeline. Avoid before-and-after photos as evidence; none of the topical studies offers a reliable one. For how GHK-Cu stacks against another popular peptide, see Matrixyl vs copper peptides. Evidence: Early / preliminary.
Will copper peptides help hair shedding from GLP-1 drugs?
No study we reviewed tested copper peptides in people shedding hair while on semaglutide or tirzepatide. We can't say whether they help.
Shedding during rapid weight loss has its own causes and time course, covered in Ozempic hair loss and does tirzepatide cause hair loss. For what patients have reported to the FDA, see hair loss and skin reports for GLP-1 drugs in FDA data. Talk to your prescriber about shedding, and don't stop or change medication on your own.
Where the evidence stops
- No published, controlled human trial of a copper peptide alone for scalp hair loss.
- No human comparison with minoxidil, finasteride or any other treatment.
- No data on how much topical GHK-Cu or AHK-Cu reaches the follicle from a standard serum.
- No AHK-Cu human hair data at all, and no GHK-Cu vs AHK-Cu comparison.
- No beard studies; one eyebrow study known only through a review (Mateescu et al., 2026).
- No dose-response, timeline or long-term scalp safety data.
- No trials in women with thinning around menopause; our menopause hair loss guide covers what is known there.
Until those gaps close, copper peptides for hair belong in the "cosmetic add-on" column, with diagnosis and treatment decisions left to a dermatologist.
FAQ
Do copper peptides regrow hair?
Regrowth from copper peptides is not proven. The human studies that reported regrowth combined copper peptide with other treatments such as growth factors, finasteride, minoxidil, dutasteride or laser, so copper's own effect is unknown. A 2026 review described the clinical evidence for GHK-Cu as sparse.
Is GHK-Cu or AHK-Cu better for hair?
No study compares GHK-Cu and AHK-Cu for hair. GHK-Cu has far more research overall, while the AHK-Cu hair data come from one lab study on isolated human follicles and cultured cells.
Are copper peptides better than minoxidil?
No human study has compared copper peptides with minoxidil head to head. The only 'similar to minoxidil' result came from a 1993 rat study of an unidentified copper-binding peptide. Talk to a dermatologist before changing any hair-loss treatment.
How long do copper peptides take to work on hair?
There is no study-based timeline for topical copper peptide serums. Waiting several months before judging any hair product is clinic convention, not evidence, and the one 15-day study tested a multi-ingredient dandruff kit.
Can copper peptides cause hair shedding?
None of the studies we reviewed reported shedding. Copper allergy is uncommon, with a weighted average of 3.8% positive copper patch tests in one review, but patch test first and see a dermatologist if irritation or shedding appears.
Do copper peptides work for beard or eyebrow growth?
We found no beard studies. A 2026 review mentions one 18-person split-face eyebrow study with positive cosmetic results, but that study did not define the GHK-Cu form or how much reached the skin.
Are GHK-Cu injections for hair safe?
Human safety data for gray-market peptides, including GHK-Cu, are scarce, and a 2026 review warns of potential for serious harm. Don't inject products sold for research use; ask a dermatologist about regulated options.
Can copper peptides help hair loss from Ozempic or Mounjaro?
No study we reviewed tested copper peptides for hair shedding in people taking semaglutide or tirzepatide. Talk to your prescriber about shedding, and don't stop or change your medication on your own.
References
- Mateescu DM, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026. Systematic evidence-mapping review; authors declare no conflicts. https://pubmed.ncbi.nlm.nih.gov/42797253/
- Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026. Systematic review, 64 records; authors declare no conflicts. https://pubmed.ncbi.nlm.nih.gov/42787770/
- Mokhtar J, et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J. 2026. Systematic review, 20 studies (18 preclinical, 2 RCTs); no hair outcomes in abstract. https://pubmed.ncbi.nlm.nih.gov/42619529/
- Patel MN, et al. An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults. Cureus. 2024. Open-label, single-center, n=32 (29 completed), 15 days; one author employed by the product maker, two by or paid by the contract research firm. https://pubmed.ncbi.nlm.nih.gov/39449909/
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018. Open-label single-arm pilot, n=1000, 8 sessions every 3 weeks; funding not stated in abstract. https://pubmed.ncbi.nlm.nih.gov/29482481/
- Bertin ACJ, et al. Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. J Cosmet Laser Ther. 2018. Case series, n=4; funding not stated in abstract. https://pubmed.ncbi.nlm.nih.gov/29452017/
- Kuceki G, et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD Int. 2025. Retrospective research letter, n=7, 5 monthly sessions, no control; no funding; one author declares pharma relationships. https://pubmed.ncbi.nlm.nih.gov/40225275/
- Liu T, et al. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioact Mater. 2024. Formulation + mouse study; authors declare no conflicts. https://pubmed.ncbi.nlm.nih.gov/38026438/
- Kapoor R, et al. QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study. Plast Reconstr Surg Glob Open. 2020. In vitro cytotoxicity + mouse injections. https://pubmed.ncbi.nlm.nih.gov/32983753/
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. Ex vivo human follicles + cultured dermal papilla cells (AHK-Cu). https://pubmed.ncbi.nlm.nih.gov/17703734/
- Trachy RE, et al. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci. 1991. Animal (mice); no abstract indexed. https://pubmed.ncbi.nlm.nih.gov/1809108/
- Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993. Review of animal studies (macaques, fuzzy rats). https://pubmed.ncbi.nlm.nih.gov/8326148/
- Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. Narrative review; authors from the peptide's originating research group. https://pubmed.ncbi.nlm.nih.gov/26236730/
- Pickart L, et al. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014. Narrative article; no study details on hair. https://pubmed.ncbi.nlm.nih.gov/25302294/
- Ogórek K, et al. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?. Molecules. 2025. Review; authors declare no conflicts. https://pubmed.ncbi.nlm.nih.gov/39795193/
- Fage SW, et al. Copper hypersensitivity. Contact Dermatitis. 2014. Review of patch-test data. https://pubmed.ncbi.nlm.nih.gov/25098945/
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. Narrative review; one author reports unrelated consulting fees. https://pubmed.ncbi.nlm.nih.gov/41966639/
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Copper peptides are cosmetic ingredients, not hair-loss treatments; see a dermatologist for diagnosis, and don't inject or ingest products sold for research use.